Cite
Izumi K, Kaneko Y, Hashizume M, et al. Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS One. 2016;11(3):e0152341doi: 10.1371/journal.pone.0152341.
Izumi, K., Kaneko, Y., Hashizume, M., Yoshimoto, K., & Takeuchi, T. (2016). Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PloS one, 11(3), e0152341. https://doi.org/10.1371/journal.pone.0152341
Izumi, Keisuke, et al. "Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)." PloS one vol. 11,3 (2016): e0152341. doi: https://doi.org/10.1371/journal.pone.0152341
Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T. Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS One. 2016 Mar 21;11(3):e0152341. doi: 10.1371/journal.pone.0152341. eCollection 2016. PMID: 26999019; PMCID: PMC4801414.
Copy
Download .nbib
